Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 351 - 400 out of 15,683

Document Document Title
WO/2011/157059A1
Isoacteoside or a pharmaceutically acceptable saltthereof which is used as an inhibitor of production, accumulation or aggregation of amyloid ╬▓peptide has effect on preventing or treating diseases or symptoms associated with amyloid ╬▓p...  
WO/2011/152618A9
The present invention relates to a method for purifying non-diffusive botulinum toxin causing local muscle paralysis, and non-diffusive botulinum toxin purified thereby, and more specifically, to a method for purifying non-diffusive botu...  
WO/2011/153277A2
Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, re...  
WO/2011/151632A1
The present invention relates to the field of nutritional support for individuals and reducing the effects of muscle conditions caused by high levels of physical activity. In particular, the invention provides dietary formulations, compo...  
WO/2011/152618A2
The present invention relates to a method for purifying non-diffusive botulinum toxin causing local muscle paralysis, and non-diffusive botulinum toxin purified thereby, and more specifically, to a method for purifying non-diffusive botu...  
WO/2011/150457A3
The present invention generally relates to compounds that inhibit haematopoietic-prostaglandin D2 synthase (H-PGDS), to compositions containing them and to their use in treating or preventing conditions and diseases associated with H-PGD...  
WO/2011/152618A4
The present invention relates to a method for purifying non-diffusive botulinum toxin causing local muscle paralysis, and non-diffusive botulinum toxin purified thereby, and more specifically, to a method for purifying non-diffusive botu...  
WO/2011/152618A3
The present invention relates to a method for purifying non-diffusive botulinum toxin causing local muscle paralysis, and non-diffusive botulinum toxin purified thereby, and more specifically, to a method for purifying non-diffusive botu...  
WO/2011/152524A1
The disclosed cell growth-promoting agent contains as active ingredient, an artificially synthesized peptide comprising (A) an amino acid sequence that configures a membrane-penetrating peptide and (B) an amino acid sequence that configu...  
WO/2011/151432A1
The present invention relates to humanised antigen binding proteins, such as antibodies, which bind to myostatin, polynucleotides encoding such antigen binding proteins, pharmaceutical compositions comprising said antigen binding protein...  
WO/2011/153277A3
Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, re...  
WO/2011/147967A1
The present invention relates to a therapeutic substance and/or medicament and methods relating to the use of said substance and/or medicament for skeletal muscle regeneration using mesenchymal stem cells (MSCs) which can be applied dire...  
WO/2011/150008A1
The present invention provides isolated human or humanized antibodies or antigen- binding fragments thereof which specifically bind to Growth and Differentiation Factor-8 (GDF8) and block GDF8 activity. The antibodies and antibody fragme...  
WO/2011/147086A1
Microvesicles containing small interfering RNAs, preparation methods and uses thereof are provided. Pharmaceutical compositions and kits comprising the microvesicles containing small interfering RNAs are also provided. Microvesicles cont...  
WO/2011/145909A3
The present invention relates to the novel use of panduratin derivatives or an extract of Boesenbergia pandurata for promoting muscle mass growth, fighting fatigue, and enhancing exercise performance capability. More particularly, the pr...  
WO/2011/143526A2
A method of treating peripheral neuropathic pain in humans resulting from a peripheral nerve injury and for treating muscle spasm in humans resulting from a peripheral nerve injury comprises applying a therapeutically effective amount of...  
WO/2011/142316A1
Disclosed is a nitrogen-containing heterocyclic compound represented by formula (I) or a pharmacologically acceptable salt thereof, which has kynurenine production inhibitory activity. (In formula (I), R6 and R7 may be the same or differ...  
WO/2011/143187A3
The invention provides biomatrix compositions comprising cross-linked lactoferrin, either alone or in combination with other organic or inorganic components. Also provided are methods of making and using the biomatrix compositions. As de...  
WO/2011/143152A3
Provided herein are methods of treatment of Amyotrophic Lateral Sclerosis comprising administration of adrenocorticotropic hormone (ACTH), or fragment, analog, complex or aggregate thereof, or any combination thereof, to an individual in...  
WO/2011/141891A1
The present invention relates to cycloundecadepsipeptide compound analogues presenting mitochondrial permeability transition pore (MPTP) inhibitory activity and reduced cytotoxicity. The present invention further relates to a pharmaceuti...  
WO/2011/143187A2
The invention provides biomatrix compositions comprising cross-linked lactoferrin, either alone or in combination with other organic or inorganic components. Also provided are methods of making and using the biomatrix compositions. As de...  
WO/2011/143008A1
The invention provides compositions and associated methods for the antisense treatment of genetic disorders, infections and various other medical conditions. In particular, embodiments of the present invention are directed to pharmaceuti...  
WO/2011/143526A9  
WO/2011/143152A2
Provided herein are methods of treatment of Amyotrophic Lateral Sclerosis comprising administration of adrenocorticotropic hormone (ACTH), or fragment, analog, complex or aggregate thereof, or any combination thereof, to an individual in...  
WO/2011/135969A1
Disclosed is a method for efficiently and conveniently producing iPS cells. Pluripotent stem cells are obtained by culturing bone marrow in the presence of granulocyte-monocyte colony-stimulating factor, and then genetically transforming...  
WO/2011/130908A1
The present invention relates to substituted pyrimidines useful as HIF prolyl hydroxylase inhibitors to treat anemia and like conditions.  
WO/2011/133985A1
A method for forming neuromuscular junctions includes forming functional neuromuscular junctions between motoneurons and muscle cells by co-culturing one or more human motoneurons and one or more human muscle cells in a substantially ser...  
WO/2011/130515A1
Aryl substituted thiazol-2-yl-piperidines and related compounds useful as modulators of survival motor neuron (SMN) protein production are provided herein. Without being bound to any particular theory it is believed the aryl substituted ...  
WO/2011/125836A1
Disclosed is a therapeutic agent or prophylactic agent that has analgesic effects on both nociceptive pain and neuropathic pain and is effective in the treatment of fibromyalgia. Specifically disclosed is a therapeutic agent or prophylac...  
WO/2011/121109A1
The present invention relates to methods and compositions for the treatment of Myotonic Dystrophy type 1 (DM1) with an AMPK activator .  
WO/2011/123456A1
Disorders such as headaches can be treated by administration of a botulinum toxin to a patient suffering therefrom, such as a migraine headache. A combined a fixed site/fixed dose and an optional follow the pain variable dosage and injec...  
WO/2011/117448A1
The invention relates to compounds for use in the treatment of diseases based on the expression of toxic transcripts. The invention relates to peptide molecules, specifically hexapeptides, for the prevention and/or treatment of diseases ...  
WO/2011/115184A1
Disclosed is an inhibitor of in vivo proteolysis, which contains, as an active ingredient, a fatty acid compound that contains one acyl group having 6-12 carbon atoms. The inhibitor of in vivo proteolysis preferably contains, as an activ...  
WO/2011/115183A1
Disclosed is a monocyclic pyrimidine derivative. To be more specific, the pyrimidine derivative is effective in the prophylaxis and/or treatment of disorders associated with signal transmission mediated by Toll-like receptors (TLR).  
WO/2011/111714A1
Disclosed are: a compound which has excellent metabolic stability and selectively binds to EP4 receptor; and a pharmaceutical product which contains the compound. Specifically disclosed is a compound represented by formula (1) (wherein R...  
WO/2011/111698A1
Disclosed is a monoclonal antibody against a biomarker capable of highly specific and effective use in the detection and diagnosis of various pathologies associated with various types of cancer nests and necrotic focuses. The monoclonal ...  
WO/2011/111694A1
Disclosed is a monoclonal antibody against a biomarker capable of highly specific and effective use in the detection and diagnosis of various pathologies associated with various types of cancer nests and necrotic focuses. The monoclonal ...  
WO/2011/108009A3
The present invention relates to a process for the preparation of substantially pure fampridine compound of structural formula (I), (II), (III) comprising nitrifying pyridine-N-oxide hydrochloride with suitable nitrating agent; reducing ...  
WO/2011/108692A1
Disclosed is an agent for preventing muscular atrophy, which has an excellent preventive effect on muscular atrophy and comprises a whey protein hydrolysate. Specifically disclosed is an agent for preventing muscular atrophy, which compr...  
WO/2011/109324A1
Compounds of formula (I) are disclosed. Compounds according to the invention bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are ...  
WO/2011/108009A2
The present invention relates to a process for the preparation of substantially pure fampridine compound of structural formula (I), (II), (III) comprising nitrifying pyridine-N-oxide hydrochloride with suitable nitrating agent; reducing ...  
WO/2011/108487A1
Disclosed is a new usage, with the goal of preventing skeletal muscle atrophy, for a specific polyphenol that inhibits the expression of a gene that causes muscular atrophy. Also disclosed is a composition which inhibits muscular atrophy...  
WO/2011/105572A1
A highly effective FAAH inhibitor, and especially a prophylactic or drug for severe pain, which can be administered orally, are needed. Provided is a pharmaceutical composition having as an active ingredient a novel heteroaryl derivative...  
WO/2011/102404A1
Disclosed are: a novel compound having an inhibitory activity on S1P lyase and capable of inducing the decrease in the number of lymphocytes or an isotope or pharmaceutically acceptable salt of the compound; and a pharmaceutical composit...  
WO/2011/101866A3
The present invention discloses a gastric retentive formulation (capsule or tablet) containing baclofen. Said formulation comprises an immediate and a sustained release part whereas the sustained release part is comprised in the core of ...  
WO/2011/096490A1
Disclosed is a prophylactic and/or therapeutic agent for rejection after transplant surgery and for diseases caused by immune system abnormalities, comprising a compound represented by formula (I) or a pharmacologically acceptable salt t...  
WO/2011/095893A1
A convenient and scalable synthesis of DGJNAc ID from D-glucuronolactone in an overall yield of 20% is provided. DGJNAc is the first highly potent and specific competitive inhibitor of GalNAcases. DGJNAc ID is also a competitive inhibito...  
WO/2011/097456A3
The present invention provides methods and compositions for enhanced transduction of an adeno-associated virus (AAV) vector comprising a heterologous nucleic acid of interest wherein the AAV vector genome is oversized relative to a wild ...  
WO/2011/097500A3
The invention provides methods for preventing loss and augmenting regeneration of skeletal muscle by decreasing the activity of the TWEAK/Fn14 system.  
WO/2011/096484A1
A read through inducer for an immature termination codon formed by a nonsense mutation, which comprises a compound represented by structure formula (A); and a therapeutic agent for nonsense-mutation-type genetic diseases, which comprises...  

Matches 351 - 400 out of 15,683